News

In a conference presentation, Dr. Imadojemu discussed the topic of afro-textured hair and various hair and scalp disorders.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.

COVID-19 vaccination in patients with cystic fibrosis generates antibody responses similar to those in the general population, according to a recent study

Analysis of phase 3 trial data show the JAK inhibitor is generally safe among patients with severe forms of the chronic hair loss disease.

In the span of a decade, agents like topical ivermectin, minocycline and benzoyl peroxide has provided more opportunities to achieve clear skin for rosacea patients.

To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.

The trial investigator reviews disparities in patient needs and treatment outcomes based on their skin complexion, 1 year after ruxolitinib's FDA approval.

Reports from the intervention group show decreased alcohol-related problems, mediated by the change in insomnia severity following treatment.

Often lost in the fray of new drug development is the need to reinforce improved behavioral health, explains a longtime dermatology nurse practitioner.

On the basis of discovery into what drives adult-onset eczema, the novel drug may provide a unique benefit for impacted patients.

A post hoc analysis shows the investigative drug significantly improved atopic dermatitis symptoms versus placebo as soon as the first week into a phase 2 trial.

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.

It's been a whirlwind few years for dermatology. The nurse practitioner discusses modern care teams, comorbid psoriatic disease, and expanding patient inclusion in clinical trials.

The treatment, developed by Intercept Pharmaceuticals, could not be approved in its present form, according to the CRL and any resubmission of the treatment for patients with NASH would require at least the successful completion of the long-term outcomes phase of the REGENERATE study.

In this interview segment, Dr. Barbieri explained the major takeaways from his conference talk on acne and rosacea with a focus on the more severe levels of these conditions.

The results show 55.4% of patients in the ketamine group had a response, compared to 41.2% of patients in the ECT group.

In this conference interview, Dr. Barbieri described some of the major takeaways from his talk on foundational tools for patients with acne and rosacea.

During this conference talk, Dr. Nicole Gunasekera spoke about options for acne scar treatments such as chemical peels and microneedling, as well as special considerations for richly-pigmented skin.

In his conference presentation, Dr. Arash Mostaghimi reviewed the ways to ensure access to the right information from a biopsy as well as how to interpret potentially confusing biopsy results.

Yan discusses how acne care strategies have been bolstered—and complicated—by pharmacotherapy and telemedicine developments.

With multiple drug classes working toward FDA indication, a dermatologists explains his strategy for managing hidradenitis suppurativa.

Findings show patients hospitalized for COVID-19 have an increased 1-year risk of venous thromboembolic disease compared with those hospitalized for influenza (HR, 1.77; 95% CI, 1.36-2.31).

The first trial observing the topical drug in children held promise for an extended indication.

The CHOP pediatric dermatology director reviews recent breakthroughs in understanding complex pathophysiology of skin diseases.

The investigator explains why he believes the PDE4 inhibitor is "as close to a perfect drug as you can hope for in seborrheic dermatitis."

The analysis of 2021 data show lung cancer screening rates increased 8.4% since 2019 to 21.2%.

Patients with high attendance rates within the lifestyle intervention group lost more weight than those with medium and low rates.